
Respiratory Infections
Latest News
Latest Videos

More News

Since its detection in early 2024, H5N1 has spread to dairy cows, poultry, and wild birds. Political factors, including leadership changes at the Centers for Disease Control and Prevention and cuts to public health resources, have worsened the situation, leading to a weakened response.

This case represents the second reported human infection with avian influenza A(H5) in Mexico, and the first confirmed case of influenza A(H5N1) in the country. The patient was a child who died from respiratory complications.

The Centers for Disease Control and Prevention (CDC) says there are now 7 outbreaks.

CDC maintains low public health risk despite more cases, the first reported death, and accelerated vaccine development to enhance pandemic preparedness.

A child who was not vaccinated succumbed to measles pulmonary failure. Additionally, increased cases and hospitalizations continue to grow greatly in the state.

European Commission Approves Merck's Capvaxive for Adult Pneumococcal Disease Prevention
New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.

Kansas now has an outbreak with at least 10 confirmed cases with an expectation from the state's health officials that there will be more.

Heather Platt, MD, discusses Merck’s ongoing research into real-world effectiveness and cost-effectiveness and offers a preview of data to be presented at ESCMID 2025.

Studies highlight the role of home visits, chest radiography, and sputum monitoring in TB prevention and treatment outcomes.

A 26% rise in childhood tuberculosis cases underscores the need for strengthened global TB control efforts.

Monday is World Tuberculosis (TB) Day, and a vaccine developed by the Gates Medical Research Institute is being studied in a phase 3 trial. If approved, the vaccine could potentially prevent pulmonary TB in adults and adolescents.

Cases in the US continue to increase, and a new analysis shows 2024 was the highest year for measles cases in Europe in 25 years.

Texas is experiencing its largest measles outbreak in 30 years and the Centers for Disease Control and Prevention's (CDC) Epidemic Intelligence Service is providing support there. Here is an overview on testing, disease presentation, and vaccination, as well as commentary on the public health impact of vaccine hesitancy, and the unintended consequences of the immunization program’s success.

The official cause of death is still under investigation by the New Mexico Office of the Medical Investigator, though the individual tested positive for the measles virus.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

New study by Gabriel Nussbaum, MD, PhD, et al, reveals how P gingivalis escapes immune detection, contributing to gum disease and increasing risks for systemic infections such as respiratory disease.

The state’s health department has confirmed all 3 cases are in people who are unvaccinated.

The CDC tracks rising human infections linked to poultry and dairy exposure, while the USDA steps up with a comprehensive strategy to combat HPAI and stabilize egg prices.

On the heels of the first death in an ongoing US-based measles outbreak, Paul Offit, MD, discusses how outbreaks are the first sign that childhood vaccination rates are starting to decline.

Tina Tan, MD, FIDSA, FPIDS, FAAP, Infectious Diseases Society of America (IDSA) president discusses the changes and offers a glimpse of what the US can expect in terms of limited access to new vaccines, increased incidence rates of disease, and new public health policy regarding immunizations.

Jeff Freiberg, MD, PhD, on the rising emerging infection concerns of dengue, mpox, measles, and H5N1 influenza in clinical practice.

Two cats became severely ill, and both owners declined to be tested.

Andrew Engeli explains Ginkgo's role in the €24 million EU-Funded RANGER project for emerging infectious disease surveillance and response.

A state official says the woman is hospitalized in another state, and had preexisting health conditions that can make people more vulnerable to illness.

In the Phase 3 trial, GSK's vaccine met all 11 primary endpoints, providing expanded options for preventing invasive meningococcal disease in individuals aged 10-25 years.


















































































































































